Lynne Jesaitis BioMarin Pharmaceutical Inc Biography Publications Institution JoVE Articles Lynne Jesaitis has not added a biography. If you are Lynne Jesaitis and would like to personalize this page please email our Author Liaison for assistance. Publications Safety, Immunogenicity, and Clinical Outcomes in Patients with Morquio A Syndrome Participating in 2 Sequential Open-label Studies of Elosulfase Alfa Enzyme Replacement Therapy (MOR-002/MOR-100), Representing 5 years of Treatment Molecular Genetics and Metabolism. Apr, 2018 | Pubmed ID: 29526614 Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study Clinical Therapeutics. Jan, 2017 | Pubmed ID: 27955919 Antibodies That Neutralize Cellular Uptake of Elosulfase Alfa Are Not Associated with Reduced Efficacy or Pharmacodynamic Effect in Individuals with Morquio A Syndrome Journal of Immunological Methods. 01, 2017 | Pubmed ID: 27789297 Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial Clinical Therapeutics. May, 2015 | Pubmed ID: 25487082 Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome Clinical Pharmacokinetics. Dec, 2014 | Pubmed ID: 25234648 Påvisning af antistoffer, som neutraliserer den cellulære optagelse af enzymet udskiftning behandlingsformer med en celle-baseret analyse Ruby Cheung1, Gregory W. deHart1, Lynne Jesaitis1, Stephen J. Zoog1, Andrew C. Melton1 1BioMarin Pharmaceutical Inc JoVE 57777 Immunology and Infection
Påvisning af antistoffer, som neutraliserer den cellulære optagelse af enzymet udskiftning behandlingsformer med en celle-baseret analyse Ruby Cheung1, Gregory W. deHart1, Lynne Jesaitis1, Stephen J. Zoog1, Andrew C. Melton1 1BioMarin Pharmaceutical Inc JoVE 57777 Immunology and Infection
